Ventricular remodeling after infarction and the extracellular collagen matrix: when is enough enough?

Left ventricular (LV) remodeling after myocardial infarction (MI) contributes significantly to LV dilation and dysfunction, and disability and death. Two paradigms, pertinent to antiremodeling therapy after MI (Figure 1), have evolved over the last 3 decades. Paradigm 1, LV remodeling is a major mechanism for disability and death,1,2 has received a great deal of attention. In contrast, paradigm 2, remodeling of the extracellular collagen matrix (ECCM) plays a major role in LV remodeling,3–7 whereby decrease, disruption, and/or defective composition of the ECCM promote LV dilation and rupture,4–7 has received little attention. A host of clinical trials showed that angiotensin-converting enzyme (ACE) inhibitors (ACE-Is) with or without aldosterone antagonists, angiotensin II (AngII) type 1 (AT1) receptor blockers (ARBs), β-adrenergic blockers or reperfusion improve outcome in survivors of MI.8–10 Concurrent evidence has underscored the importance of preserving the ECCM during healing after MI.2–7 However, the antifibrotic action of ACE-Is, aldosterone antagonists and ARBs on ECCM in the infarct zone (IZ) and noninfarct zone (NIZ),6,7,9,11 and the reperfusion-induced damage to the ECCM in the IZ,5,7,12 remain unreconciled with the benefits.8–10,13 Nevertheless, excessive ECCM, as in dilated ischemic cardiomyopathy after remote MI,14,15 can contribute to LV diastolic dysfunction and poor outcome,6 suggesting that antifibrotic drugs that target excess ECCM might be a logical therapeutic approach. This review focuses on the role of the ECCM in the evolution of LV remodeling after MI and the potential impact of therapies that target the ECCM. Figure 1. Role of ECCM in ventricular remodeling; shown are 2 paradigms for adverse outcome after MI. Top, Cascade from acute transmural MI to heart failure and death. Left, Diagrams of short- and long-axis sections of the heart after anterior MI. Middle, Diagrams showing topographic changes in short-axis sections during healing …

[1]  N. Hollenberg,et al.  Literature alert , 2002 .

[2]  Cardiac fibroblasts are predisposed to convert into myocyte phenotype: Specific effect of transforming growth factor β , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[3]  B. Jugdutt Prevention of ventricular remodelling post myocardial infarction: timing and duration of therapy. , 1993, The Canadian journal of cardiology.

[4]  A. Luttun,et al.  Inhibition of plasminogen activators or matrix metalloproteinases prevents cardiac rupture but impairs therapeutic angiogenesis and causes cardiac failure , 1999, Nature Medicine.

[5]  L. Leinwand,et al.  Localization of types I, III and IV collagen mRNAs in rat heart cells by in situ hybridization. , 1989, Journal of molecular and cellular cardiology.

[6]  J. Davies,et al.  Molecular Biology of the Cell , 1983, Bristol Medico-Chirurgical Journal.

[7]  R. Zak Development and Proliferative Capacity of Cardiac Muscle Cells , 1974, Circulation research.

[8]  B. Jugdutt Left ventricular rupture threshold during the healing phase after myocardial infarction in the dog. , 1987, Canadian journal of physiology and pharmacology.

[9]  R. Taylor,et al.  Collagen synthesis and content in right ventricular hypertrophy in the dog. , 1981, The American journal of physiology.

[10]  T. Ichiki,et al.  Targeted Deletion of Angiotensin II Type 2 Receptor Caused Cardiac Rupture After Acute Myocardial Infarction , 2002, Circulation.

[11]  B. Jugdutt Remodeling of the myocardium and potential targets in the collagen degradation and synthesis pathways. , 2003, Current drug targets. Cardiovascular & haematological disorders.

[12]  B. Jugdutt,et al.  Functional impact of remodeling during healing after non-Q wave versus Q wave anterior myocardial infarction in the dog. , 1992, Journal of the American College of Cardiology.

[13]  K. Weber,et al.  Regulation of collagen degradation in the rat myocardium after infarction. , 1995, Journal of molecular and cellular cardiology.

[14]  J. Covell Factors influencing diastolic function. Possible role of the extracellular matrix. , 1990, Circulation.

[15]  M. Pfeffer,et al.  Ventricular Remodeling After Myocardial Infarction: Experimental Observations and Clinical Implications , 1990, Circulation.

[16]  Douglas L Mann,et al.  Inflammatory mediators and the failing heart: past, present, and the foreseeable future. , 2002, Circulation research.

[17]  B. Brodsky,et al.  The triple‐lielix motif in proteins , 1995, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[18]  J. Woessner,et al.  The Matrix Metalloproteinase Family , 1998 .

[19]  M. Eghbali,et al.  Collagen chain mRNAs in isolated heart cells from young and adult rats. , 1988, Journal of molecular and cellular cardiology.

[20]  B. Pitt,et al.  Eplerenone , a Selective Aldosterone Blocker , in Patients with Left Ventricular Dysfunction after Myocardial Infarction , 2003 .

[21]  Nag Ac,et al.  Study of non-muscle cells of the adult mammalian heart: a fine structural analysis and distribution. , 1980 .

[22]  Peter Gaudron,et al.  Progressive Left Ventricular Dysfunction and Remodeling After Myocardial Infarction Potential Mechanisms and Early Predictors , 1993, Circulation.

[23]  B. Strauss,et al.  Matrix remodeling in experimental and human heart failure: a possible regulatory role for TIMP-3. , 2003, American journal of physiology. Heart and circulatory physiology.

[24]  S. Factor,et al.  Alterations of the myocardial skeletal framework in acute myocardial infarction with and without ventricular rupture. A preliminary report. , 1987, The American journal of cardiovascular pathology.

[25]  F. Spinale,et al.  Myocardial and interstitial matrix metalloproteinase activity after acute myocardial infarction in pigs. , 2001, American journal of physiology. Heart and circulatory physiology.

[26]  F. Alla,et al.  Limitation of Excessive Extracellular Matrix Turnover May Contribute to Survival Benefit of Spironolactone Therapy in Patients With Congestive Heart Failure: Insights From the Randomized Aldactone Evaluation Study (RALES) , 2000, Circulation.

[27]  B. Jugdutt,et al.  Rate of collagen deposition during healing and ventricular remodeling after myocardial infarction in rat and dog models. , 1996, Circulation.

[28]  S. Kumar,et al.  Co-expression of tissue inhibitor and matrix metalloproteinase in myocardium. , 1995, Journal of molecular and cellular cardiology.

[29]  J. Cleutjens,et al.  The role of matrix metalloproteinases in heart disease. , 1996, Cardiovascular research.

[30]  D. Etherington Collagen degradation , 1977, Connective tissue research.

[31]  M. Eghbali,et al.  Cardiac fibroblasts are predisposed to convert into myocyte phenotype: specific effect of transforming growth factor beta. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[32]  J. Covell,et al.  Increase in Cross‐Linking of Type I and Type III Collagens Associated With Volume‐Overload Hypertrophy , 1988, Circulation research.

[33]  Identification of patients prone to infarct expansion by the degree of regional shape distortion on an early two–dimensional echocardiogram after myocardial infarction , 1990, Clinical cardiology.

[34]  G Olivetti,et al.  Side-to-side slippage of myocytes participates in ventricular wall remodeling acutely after myocardial infarction in rats. , 1990, Circulation research.

[35]  B. Pitt,et al.  Eplerenone, a Selective Aldosterone Blocker, in Patients with Left Ventricular Dysfunction after Myocardial Infarction , 2003 .

[36]  A. Becker,et al.  Remodeling after myocardial infarction in humans is not associated with interstitial fibrosis of noninfarcted myocardium. , 1997, Journal of the American College of Cardiology.

[37]  S. Yusuf,et al.  Effect of acute angiotensin converting enzyme inhibition on left ventricular diastolic filling in patients with congestive heart failure: Relation to right ventricular volume , 1990 .

[38]  H. Matsubara,et al.  Pathophysiological role of angiotensin II type 2 receptor in cardiovascular and renal diseases. , 1998, Circulation research.

[39]  K. Weber,et al.  Extracellular matrix remodeling in heart failure: a role for de novo angiotensin II generation. , 1997, Circulation.

[40]  J. Rouleau,et al.  Endothelin A receptor blockade causes adverse left ventricular remodeling but improves pulmonary artery pressure after infarction in the rat. , 1998, Circulation.

[41]  E. Miller Collagen structure and function , 1992 .

[42]  S. Tyagi Proteinases and myocardial extracellular matrix turnover , 1997, Molecular and Cellular Biochemistry.

[43]  K. Weber,et al.  Infarct scar: a dynamic tissue. , 2000, Cardiovascular research.

[44]  A. Nag,et al.  Study of non-muscle cells of the adult mammalian heart: a fine structural analysis and distribution. , 1980, Cytobios.

[45]  D. Mann,et al.  Activation of matrix metalloproteinases in the failing human heart: breaking the tie that binds. , 1998, Circulation.

[46]  E. Antman,et al.  Fatal cardiac rupture among patients treated with thrombolytic agents and adjunctive thrombin antagonists: observations from the Thrombolysis and Thrombin Inhibition in Myocardial Infarction 9 Study. , 1999, Journal of the American College of Cardiology.

[47]  B. Jugdutt Myocardial salvage by intravenous nitroglycerin in conscious dogs: loss of beneficial effect with marked nitroglycerin-induced hypotension. , 1983, Circulation.

[48]  E. Sonnenblick,et al.  Profound structural alterations of the extracellular collagen matrix in postischemic dysfunctional ("stunned") but viable myocardium. , 1987, Journal of the American College of Cardiology.

[49]  J. Foidart,et al.  Matrix metalloproteinase family. , 1995, Cell biology international.

[50]  T K Borg,et al.  The collagen network of the heart. , 1979, Laboratory investigation; a journal of technical methods and pathology.

[51]  U. Ryan,et al.  Voltage-gated and receptor-mediated ionic currents in the membrane of endothelial cells. , 1989, Journal of molecular and cellular cardiology.

[52]  C A Beltrami,et al.  Structural basis of end-stage failure in ischemic cardiomyopathy in humans. , 1994, Circulation.

[53]  H. Schunkert,et al.  Angiotensin‐Converting Enzyme Inhibition Prolongs Survival and Modifies the Transition to Heart Failure in Rats With Pressure Overload Hypertrophy Due to Ascending Aortic Stenosis , 1994, Circulation.

[54]  B. Jugdutt,et al.  Myocardial infarct expansion during indomethacin or ibuprofen therapy for symptomatic post infarction pericarditis. Influence of other pharmacologic agents during early remodelling. , 1989, The Canadian journal of cardiology.

[55]  P. Armstrong,et al.  Remodeling and reparation of the cardiovascular system. , 1992, Journal of the American College of Cardiology.

[56]  I. K. Cohen,et al.  Wound Healing: Biochemical & Clinical Aspects , 1992 .

[57]  B. Pitt,et al.  EPLERENONE POST-ACUTE MYOCARDIAL INFARCTION HEART FAILURE EFFICACY AND SURVIVAL STUDY INVESTIGATORS. EPLERENONE, A SELECTIVE ALDOSTERONE BLOCKER, IN PATIENTS WITH LEFT VENTRICULAR DYSFUNCTION AFTER MYOCARDIAL INFARCTION , 2003 .

[58]  B. Jugdutt,et al.  Effect of angiotensin-converting enzyme inhibition on infarct collagen deposition and remodelling during healing after transmural canine myocardial infarction. , 1997, Canadian Journal of Cardiology.

[59]  M. Flather,et al.  ACE inhibitor use in patients with myocardial infarction. Summary of evidence from clinical trials. , 1995, Circulation.

[60]  B. Jugdutt Effect of reperfusion on ventricular mass, topography, and function during healing of anterior infarction. , 1997, The American journal of physiology.